Year archive

Apontis Pharma AG — 2024 filings

All 27 regulatory filings released by Apontis Pharma AG (APPH) in 2024, sourced directly from the official regulator.

27 Filings

2024 Period

2024 filings (27)

Filing	Released	Lang
Jahresabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023 Audit Report / Information FY 2023	2024-12-23	German
APONTIS PHARMA AG: Thomas Milz, Sale: The sale was made via a joint custody account with Ariane Milz (person closely associated with a person discharging managerial responsibilities). Director's Dealing	2024-12-12	English
APONTIS PHARMA AG: Thomas Milz, Sale: The sale was made via a joint custody account with Ariane Milz (person closely associated with a person discharging managerial responsibilities). Director's Dealing	2024-12-11	English
APONTIS PHARMA AG: Thomas Zimmermann, sell Director's Dealing	2024-12-10	English
Konzernabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022 Annual Report FY 2022	2024-11-27	German
APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentivas Voluntary Public Purchase Offer Waived M&A Activity	2024-11-22	English
APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentivas Voluntary Public Purchase Offer Waived M&A Activity	2024-11-21	English
APONTIS PHARMA reports profitable revenue growth for Single Pill combinations in 9M 2024 revenue guidance adjusted Earnings Release 9M 2024	2024-11-07	English
Management Board and Supervisory Board of APONTIS PHARMA AG recommend accepting Zentivas public tender offer M&A Activity	2024-10-30	English
APONTIS PHARMA and Zentiva entered into partnership for future growth Zentiva will launch a voluntary public purchase offer M&A Activity	2024-10-16	English
APONTIS PHARMA and Zentiva enter into investment agreement Zentiva will launch a voluntary public purchase offer Delisting Announcement	2024-10-16	English
Konzernabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023 Governance Information FY 2023	2024-09-13	German
APONTIS PHARMA with profitable revenue growth for Single Pill combinations in the first half of 2024 forecast for the full year confirmed Earnings Release H1 2024	2024-08-09	English
Half-yearly financial statements 2024 Interim / Quarterly Report H2 2024	2024-08-09	English
APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board with a view to the strategic development of the Company Board/Management Information	2024-06-27	English
APONTIS PHARMA continues to gear organization towards growth and internationalization Renowned industry expert leads supply chain management Board/Management Information	2024-06-04	English
APONTIS PHARMA AG: Thomas Milz, buy Director's Dealing	2024-05-14	English
APONTIS PHARMA AG: be executive GmbH, buy Director's Dealing	2024-05-14	English
APONTIS PHARMA AG: Thomas Zimmermann, buy Director's Dealing	2024-05-13	English
APONTIS PHARMA starts financial year 2024 with growth in revenue of Single Pill combinations and positive net result forecast for full-year 2024 confirmed Earnings Release Q1 2024	2024-05-08	English
APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast Earnings Release FY 2024	2024-04-05	English
APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications Regulatory Filings	2024-04-05	English
APONTIS PHARMA expects profitable growth again in 2024 Earnings Release FY 2023	2024-03-28	English
Jahresabschluss 2023 Audit Report / Information FY 2023	2024-03-28	German
Annual financial statements 2023 Annual Report FY 2023	2024-03-28	English
Jahresabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022 Audit Report / Information FY 2022	2024-02-26	German
APONTIS PHARMA successfully completes performance and efficiency improvement program Earnings Release FY 2023	2024-02-06	English